<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02969252</url>
  </required_header>
  <id_info>
    <org_study_id>CB-01-11/27</org_study_id>
    <nct_id>NCT02969252</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety Study of Rifamycin SV-MMX速 600 mg Tablets After Single and Multiple t.i.d. Doses in Healthy Male and Female Volunteers</brief_title>
  <official_title>Pharmacokinetics and Safety Study of Rifamycin SV-MMX速 600 mg Tablets After Single and Multiple t.i.d. Doses in Healthy Male and Female Volunteers. Single and Multiple Dose, Open Label, Pharmacokinetics and Safety Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cosmo Technologies Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cosmo Technologies Ltd</source>
  <brief_summary>
    <textblock>
      The objective of the study was to evaluate the pharmacokinetics and the safety of rifamycin
      SV after single and multiple doses of Rifamycin SV-MMX速 600 mg tablets administered to male
      and female healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1</time_frame>
    <description>Cmax,0-24 h</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1</time_frame>
    <description>Cmax,0-6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tmax</measure>
    <time_frame>Day 1</time_frame>
    <description>tmax,0-24</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tmax</measure>
    <time_frame>Day 1</time_frame>
    <description>tmax,0-6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Day 1</time_frame>
    <description>AUC 0-24</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Day 1</time_frame>
    <description>AUC 0-6</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Open label</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single and multiple dose, open label, pharmacokinetics and safety study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifamycin SV-MMX速 600</intervention_name>
    <arm_group_label>Open label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent: signed written informed consent before inclusion in the study

          2. Sex and Age: men and women, 18-55 year old inclusive

          3. Body Mass Index: 18.5-30 kgm2 inclusive

          4. Vital signs: systolic blood pressure 100-139 mmHg, diastolic blood pressure 50-89
             mmHg, heart rate 50-90 bpm, measured after 5 min at rest in the sitting position

          5. Full comprehension: ability to comprehend the full nature and purpose of the study,
             including possible risks and side effects; ability to co-operate with the investigator
             and to comply with the requirements of the entire study

          6. Fertility (women only): women of non-child-bearing potential or in post-menopausal
             status for at least 1 year.

        For all female subjects, pregnancy test result had to be negative at screening and Day -1

        Exclusion Criteria:

          1. ECG 12-leads (supine position): clinically significant abnormalities

          2. Physical findings: clinically significant abnormal physical findings which could
             interfere with the objectives of the study

          3. Laboratory analyses: clinically significant abnormal laboratory values indicative of
             physical illness

          4. Allergy: ascertained or presumptive hypersensitivity to the active principle and/or
             formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in
             general, which the investigator considered could affect the outcome of the study

          5. Diseases: significant history of renal, hepatic, gastrointestinal, cardiovascular,
             respiratory, skin, haematological, endocrine or neurological diseases that could
             interfere with the aim of the study

          6. Medications: medications, including over the counter medications and herbal remedies,
             for 2 weeks before the start of the study

          7. Investigative drug studies: participation in the evaluation of any investigational
             product for 3 months before this study. The 3-month interval was calculated as the
             time between the first calendar day of the month that follows the last visit of the
             previous study and the first day of the present study

          8. Blood donation: blood donations for 3 months before this study

          9. Drug, alcohol, caffeine, tobacco: history of drug, alcohol (more than 1 drink a day
             for females and more than 2 drinks a day for males, defined according to the USDA
             Dietary Guidelines 2010), caffeine (more than 5 cups coffee/tea/day) or tobacco abuse
             (10 cigarettes a day)

         10. Abuse drug test: positive result at the drug test at screening or Day-1

         11. Alcohol test: positive alcohol breath test at Day -1

         12. Diet: abnormal diets (less than1600 or more than 3500 kcal/day) or substantial changes
             in eating habits in the 4 weeks before this study; vegetarians

         13. Pregnancy (females only): positive or missing pregnancy test at screening or Day -1,
             pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2016</study_first_submitted>
  <study_first_submitted_qc>November 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2016</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifamycins</mesh_term>
    <mesh_term>Rifamycin SV</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

